However, it is widely suggested that the loss of heterozygosity (LOH) or mutations in TIF1-γ genes inside tumors induce cross-reactivity against wild-type TIF1-γ antigens in the muscle and skin and subsequently leads to cancer-associated anti-TIF1-γ antibody-positive DM development [14, 15]. The gene discussed is TRIM33; the disease is cancer.